A Phase IIIB/IV, Open-Label, Multi-Center Trial to Evaluate the Safety, Tolerability, and Efficacy of HIV-1 Infected Subjects Switching Their Current Protease-Inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks

Grants and Contracts Details

StatusFinished
Effective start/end date4/1/05 → 6/30/11

Funding

  • GlaxoSmithKline: $10,203.00